Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06911320 · ClinicalTrials.gov registry record · Phase 1
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
A Phase 1 study of Hepatic Impairment and Renal Impairment, sponsored by Atea Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 2
- Study locations
NCT06911320 is a Phase 1 study of Hepatic Impairment and Renal Impairment that is actively recruiting participants, run by Atea Pharmaceuticals. The registered enrollment target is 28 participants, below the 36-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (22% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT06911320, a Phase 1 study of Hepatic Impairment and Renal Impairment, is actively recruiting participants, sponsored by Atea Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 2
- Study locations
Study Summary
To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose
Conditions Studied
Interventions
- DRUG Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination
Study Locations (2)
Florida
- Atea Study Site - Orlando
- Atea Study Site - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2025-04-09 |
| Est. Completion | 2025-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06911320
The ClinicalTrials.gov registry entry for NCT06911320 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36-participant average among 48 other Hepatic Impairment trials with a reported enrollment target (22% lower). The listed sponsor is Atea Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hepatic Impairment appearing as the primary indexed condition, and to 1 intervention - of which Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination is the first listed.
NCT06911320 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06911320 about?
NCT06911320 is a clinical study titled "Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function". To Assess the Effect of Severe Hepatic or Renal Impairment on the Pharmacokinetics of Bemnifosbuvir/Ruzasvir After a Single Dose
What is the current status of trial NCT06911320?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2025-04-09. Estimated completion is 2025-11.
What conditions does trial NCT06911320 study?
This clinical trial studies the following conditions: Hepatic Impairment, Renal Impairment, Healthy Volunteer Study.
What interventions are being tested in trial NCT06911320?
The interventions under investigation include: Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination (DRUG).
Who is sponsoring clinical trial NCT06911320?
This trial is sponsored by Atea Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06911320 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatic Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
RECRUITING · Phase 1
-
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
RECRUITING · Phase 1
-
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
RECRUITING · Phase 1
-
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
RECRUITING · Phase 1
-
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.